U5P.F VIVANI MED.INC. NEW O.N.
- Market cap
- EUR 83.9M
- P/E
- -
- P/B
- 5.10x
- ROE
- -138.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is U5P.F undervalued?
Graham numberThe Graham number of VIVANI MED.INC. NEW O.N. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
VIVANI MED.INC. NEW O.N. fundamental analysis
No fundamental analysis for VIVANI MED.INC. NEW O.N. yet.
VIVANI MED.INC. NEW O.N. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight m…
Full company profileVIVANI MED.INC. NEW O.N. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
VIVANI MED.INC. NEW O.N. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -13.3M | -21.2M | -27.0M | -24.7M | -27.6M | -27.4M |
| EBITDA | - | -20.9M | -26.6M | -24.3M | -27.1M | -26.9M |
| Net Income | -12.8M | -13.9M | -25.7M | -23.5M | -26.6M | -26.3M |
| EPS | -0.25 | -0.27 | -0.50 | -0.40 | -0.35 | -0.29 |
| Balance Sheet | ||||||
| Total Assets | 5.45M | 51.1M | 45.8M | 41.6M | 39.4M | 41.6M |
| Total Liabilities | 2.99M | 6.82M | 25.0M | 24.0M | 23.7M | 22.7M |
| Shareholders' Equity | 2.47M | 44.3M | 20.8M | 17.6M | 15.7M | 19.0M |
| Cash & Short-term Investments | 2.18M | 45.1M | 20.7M | 18.4M | 16.2M | 19.9M |
| Cash Flow | ||||||
| Operating Cash Flow | -11.0M | -18.8M | -23.7M | -20.8M | -24.3M | -24.5M |
| Capital Expenditure | 572K | 338K | 887K | 556K | 1.17M | 204K |
| Free Cash Flow | -11.5M | -19.1M | -24.6M | -21.3M | -25.5M | -24.7M |
| Ratios | ||||||
| ROE | -518.2% | -31.3% | -123.6% | -133.4% | -169.2% | -138.7% |
| ROA | -234.2% | -27.2% | -56.0% | -56.5% | -67.5% | -63.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
VIVANI MED.INC. NEW O.N. dividends
VIVANI MED.INC. NEW O.N. has not paid dividends in the last 5 fiscal years.
Who owns VIVANI MED.INC. NEW O.N.
- Insiders 55.37%
- Institutions 5.72%
- Public & others 38.91%
- Shares outstanding 90.2M
- Free float 38.9M
VIVANI MED.INC. NEW O.N. company profile
- Company name
- VIVANI MED.INC. NEW O.N.
- Ticker
- U5P.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 42
- Fiscal year end
- December
- Address
- 1350 South Loop Road, Alameda, CA, United States, 94502
- Phone
- 415 506 8462
- Website
- vivani.com
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
VIVANI MED.INC. NEW O.N. management
5- Dr. Adam Mendelsohn Ph.D.Co-Founder, CEO & Director · born 1982
- Mr. Anthony Edward Baldor M.B.A.Chief Financial Officer · born 1982
- Mr. Truc Le M.B.A.Chief Operations Officer · born 1953
- Dr. Lisa E. Porter M.D.Chief Medical Officer · born 1964
- Mr. Donald Dwyer M.B.A.Chief Business Officer & Corporate Secretary · born 1959